Fennec Pharmaceuticals Inc. (FRA:RV41)
Germany
· Delayed Price · Currency is EUR | Market Cap | 221.66M |
| Revenue (ttm) | 33.06M |
| Net Income (ttm) | -5.91M |
| Shares Out | n/a |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | 12.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 6.35 |
| Previous Close | 6.50 |
| Day's Range | 6.35 - 6.50 |
| 52-Week Range | 4.30 - 8.25 |
| Beta | n/a |
| RSI | 46.88 |
| Earnings Date | Nov 19, 2025 |
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated ... [Read more]
Financial Performance
In 2024, Fennec Pharmaceuticals's revenue was $47.54 million, an increase of 123.69% compared to the previous year's $21.25 million. Losses were -$436,000, -97.28% less than in 2023.
Financial numbers in USD Financial StatementsNews
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK when Compared with Historically Reported Rates of ...
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates o...
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...
Fennec Pharmaceuticals (FENC) Eliminates Debt with Convertible Notes Buyback
Fennec Pharmaceuticals (FENC) Eliminates Debt with Convertible Notes Buyback
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the...
Fennec Pharmaceuticals (FENC) Plans $5.025M Share Offering in Canada
Fennec Pharmaceuticals (FENC) Plans $5.025M Share Offering in Canada
Fennec Pharmaceuticals plans share offering in Canada to raise up to $5 million
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced tha...
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the...
Fennec Pharmaceuticals (FENC) Announces Public Offering of Common Shares
Fennec Pharmaceuticals (FENC) Announces Public Offering of Common Shares
Fennec Pharmaceuticals (FENC) Plans Public Share Offering
Fennec Pharmaceuticals (FENC) Plans Public Share Offering
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced tha...
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC)
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC)
Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Jeffrey S. Hackman - CEO & Director Robert C.
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Pra...
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy cir...
Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer...
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...
Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Robert Andrade - CFO Jeff Hackman - CEO and Board Member Conference Call Part...
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
~ Achieved Full-Year PEDMARK ® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK ® Q4 2024 Net Product Sales of $7.9 Million ~
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com...
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and y...
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management
~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ...